# Precigen, Inc. Common Stock (PGEN)

> Precigen, Inc. Common Stock (PGEN) trades at $4.47 (+5.92%) as of 7:53:28 PM EST on Nov 6, 2026, -41.18% over the past month. Market cap is $1.6B, with 10.2 days to cover in short interest.

Canonical: https://massive.com/quote/pgen
Data as of: 2026-11-07T00:53:28.030Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$4.47** +0.25 (+5.92%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$4.45** -0.02 (-0.45%)
As of 7:53:28 PM EST on Nov 6, 2026 · After hours

## Stock performance

How Precigen, Inc. Common Stock (PGEN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +5.92% |
| 1W | -35.59% |
| 1M | -41.18% |
| YTD | +6.94% |
| 1Y | +11.75% |
| 52-wk range | $3.04 – $8.98 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for PGEN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $4.03 – $4.48 |
| Open | $4.32 |
| Prev close | $4.22 |
| Volume | 9.24M |
| Market cap | $1.6B |
| Shares out | 356.51M |

## Valuation and profitability ratios

Valuation and profitability ratios for Precigen, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 18.70 |
| P/B | 36.78 |
| P/FCF | — |
| ROE | -772.7% |
| ROA | -197.7% |
| Debt/Equity | 2.15 |
| Div yield | 0.00% |

As of Nov 6, 2026

## Insider trading

[Precigen, Inc. Common Stock (PGEN) insider trading](https://massive.com/quote/pgen/insider-trading.md): open-market Form 4 buys and sells by Precigen, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Precigen, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 4, 2026, reporting its financial results for the quarter ended September 30, 2026.”
- Aug 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 4, 2026, reporting its financial results for the quarter ended June 30, 2026.”
- Jun 24, 2026 · Annual meeting results
  “At the 2026 Annual Meeting, the Company's stockholders (i) elected each of the persons listed below as a director for a one-year term, (ii) ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, (iii) approved a non-binding advisory resolution approving the compensation of the named executive officers, and (iv) approved the 2023 Plan Amendment No. 3.”
- May 13, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 13, 2026, reporting its financial results for the quarter ended March 31, 2026.”
- Nov 13, 2025 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 13, 2025, reporting its financial results for the quarter ended September 30, 2025.”

## PGEN short interest

How heavily PGEN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 10.2 |
| Short interest | 46.39M |
| Avg volume | 4.54M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## PGEN news

The latest news and headlines about Precigen, Inc. Common Stock (PGEN).

- [Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates](https://www.zacks.com/stock/news/3023487/precigen-inc-pgen-q3-earnings-and-revenues-miss-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3023487) · Zacks Investment Research · Nov 4, 2026 · neutral sentiment
- [Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?](https://www.zacks.com/stock/news/3020717/precigen-gears-up-to-report-q3-earnings-what-can-investors-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-3020717) · Zacks Investment Research · Nov 2, 2026 · negative sentiment
- [Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus](https://www.zacks.com/stock/news/2999879/beat-the-market-like-zacks-thermo-fisher-cricut-shopify-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2999879) · Zacks Investment Research · Oct 5, 2026 · positive sentiment
- [4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike](https://www.zacks.com/stock/news/2999327/4-low-beta-healthcare-stocks-to-buy-amid-fears-of-another-rate-hike?cid=CS-ZC-FT-analyst_blog|investment_ideas-2999327) · Zacks Investment Research · Oct 2, 2026 · positive sentiment
- [Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?](https://www.zacks.com/stock/news/2998591/precigen-pgen-soars-6-3-is-further-upside-left-in-the-stock?cid=CS-ZC-FT-fundamental_analysis|daily_price_change_5%-2998591) · Zacks Investment Research · Oct 1, 2026 · positive sentiment

## About Precigen, Inc. Common Stock

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 47 |
| Listed | Aug 8, 2013 |

[Company website](http://www.precigen.com)

## FAQ

### What is the Precigen, Inc. Common Stock (PGEN) stock price today?

Precigen, Inc. Common Stock (PGEN) is trading at $4.47 (+5.92% on the day) as of 7:53:28 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Precigen, Inc. Common Stock?

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms.

### What is the short interest in PGEN?

As of Oct 15, 2026, PGEN has 46.39M shares short and 10.2 days to cover.

### What exchange is PGEN listed on?

Precigen, Inc. Common Stock (PGEN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time PGEN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PGEN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Precigen, Inc. Common Stock (PGEN) insider trading](https://massive.com/quote/pgen/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms